+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Hodgkin's Lymphoma - Pipeline Insight, 2021

  • ID: 5240452
  • Drug Pipelines
  • February 2021
  • Region: Global
  • 60 pages
  • DelveInsight

FEATURED COMPANIES

  • 4SC
  • ACD Therapeutics
  • Affimed Therapeutics
  • Cstone Pharmaceuticals
  • TG Therapeutics
This “Hodgkin’s Lymphoma - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Hodgkin’s Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Hodgkin’s Lymphoma Understanding

Hodgkin’s Lymphoma: Overview

Hodgkin’s Lymphoma also known as Hodgkin’s disease is a type of blood cancer that initiate in the lymphatic system (part of immune system that help to get rid of waste and fight against infections). This disease is the most common type of cancer of lymphatic system. Hodgkin disease originate in the WBCs and grow abnormally and spread beyond the lymphatic system. As the disease progress it invades into other organs and can damage their function. Hodgkin’s lymphoma are more common in men than women and affect individuals between the age of 15-40 and above 55 years. The exact etiology of Hodgkin’s Lymphoma is not clear however, DNA mutation, and infection of Epstein-Barr virus (EBV), which causes mononucleosis can be the reason behind the development of Hodgkin’s lymphoma.

"Hodgkin’s Lymphoma - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hodgkin’s Lymphoma pipeline landscape is provided which includes the disease overview and Hodgkin’s Lymphoma treatment guidelines. The assessment part of the report embraces, in depth Hodgkin’s Lymphoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hodgkin’s Lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Hodgkin’s Lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve Hodgkin’s Lymphoma.
Hodgkin’s Lymphoma Emerging Drugs Chapters

This segment of the Hodgkin’s Lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Hodgkin’s Lymphoma Emerging Drugs
  • AFM 13: Affimed Therapeutics
Affimed Therapeutics’ new drug candidate, AFM 13, is a type of immunotherapy, currently in the development stage for the treatment of Hodgkin’s disease. Phase I data demonstrated good efficacy, and tolerability. The drug has been designated with orphan drug status. The drug does not kill cancer cells directly but encourages the body’s own immune system to seek out and destroy the cells. It works by activating a type of immune cell, called a natural killer (NK) cell, and directing them to destroy the cancerous cells.
  • Camidanlumab tesirine: ACD Therapeutics
ACD Therapeutics “breakthrough” drug carnidanlumab tesirine is currently being evaluated for the treatment of Hodgkin’s lymphoma and has demonstrated safety and efficacy in phase I trials. It is an antibody drug conjugate against CD25 expressed on the surface of cancerous cells.

Hodgkin’s Lymphoma: Therapeutic Assessment

This segment of the report provides insights about the different Hodgkin’s Lymphoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Hodgkin’s Lymphoma

There are approx. 10+ key companies which are developing the therapies for Hodgkin’s Lymphoma. The companies which have their Hodgkin’s Lymphoma drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Affimed Therapeutics and others.

The report covers around 10+ products under different phases of clinical development like
  • Mid-stage products (Phase II and Phase I/II)
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
Route of Administration

Hodgkin’s Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Subcutaneous
  • Intravenous
  • Oral
  • Intramuscular
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Small molecules
  • Natural metabolites
  • Monoclonal antibodies
  • Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hodgkin’s Lymphoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hodgkin’s Lymphoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hodgkin’s Lymphoma drugs.

Hodgkin’s Lymphoma Report Insights
  • Hodgkin’s Lymphoma Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Hodgkin’s Lymphoma Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions Answered

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Hodgkin’s Lymphoma drugs?
  • How many Hodgkin’s Lymphoma drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hodgkin’s Lymphoma?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Hodgkin’s Lymphoma therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Hodgkin’s Lymphoma and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Affimed Therapeutics
  • ACD Therapeutics
  • Cstone Pharmaceuticals
  • 4SC
  • TG Therapeutics
Key Products
  • AFM 13
  • Camidanlumab tesirine
  • Sugemalimab
  • Resminostat
  • TGR-1202
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 4SC
  • ACD Therapeutics
  • Affimed Therapeutics
  • Cstone Pharmaceuticals
  • TG Therapeutics
Introduction

Executive Summary

Hodgkin's Lymphoma: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management
Pipeline Therapeutics
  • Comparative Analysis
Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
Hodgkin's Lymphoma - Analytical Perspective

In-depth Commercial Assessment
  • Hodgkin's Lymphoma companies' collaborations, Licensing, Acquisition - Deal Value Trends
Hodgkin's Lymphoma Collaboration Deals
  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
  • Comparative Analysis
AFM 13:Affimed Therapeutics
  • Product Description
  • Research and Development
  • Product Development Activities
Mid Stage Products (Phase II)
  • Comparative Analysis
Camidanlumab tesirine: ACD Therapeutics
  • Product Description
  • Research and Development
  • Product Development Activities
Pre-clinical and Discovery Stage Products
  • Comparative Analysis
  • Product Description
  • Research and Development
  • Product Development Activities
Inactive Products
  • Comparative Analysis
Hodgkin's Lymphoma Key Companies

Hodgkin's Lymphoma Key Products

Hodgkin's Lymphoma - Unmet Needs

Hodgkin's Lymphoma - Market Drivers and Barriers

Hodgkin's Lymphoma - Future Perspectives and Conclusion

Hodgkin's Lymphoma Analyst Views

Hodgkin's Lymphoma Key Companies

Appendix

List of Tables
Table 1 Total Products for Hodgkin's Lymphoma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures
Figure 1 Total Products for Hodgkin's Lymphoma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown
  • Affimed Therapeutics
  • ACD Therapeutics
  • Cstone Pharmaceuticals
  • 4SC
  • TG Therapeutics
Note: Product cover images may vary from those shown
Adroll
adroll